Chadi Nabhan
YOU?
Author Swipe
View article: Supplementary Figure 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Supplementary Figure 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Open
Tumor mutation burden (muts/Mb) of ATM and BRCA2 mutant mPCs.
View article: Supplementary Table 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Supplementary Table 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Open
Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).
View article: Supplementary Figure 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Supplementary Figure 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Open
AR activities and NEPC signatures in ATM- and BRCA2- mutated tumors.
View article: Figure S2 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S2 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Fig S2
View article: Figure S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Fig S3
View article: Table S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Supplemental table 1
View article: Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Supplemental table 3
View article: Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Fig S1
View article: Table S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Supplemental table 4
View article: Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Fig S4
View article: Data from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Data from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Immune checkpoint inhibitors (ICI) have changed the treatment paradigm for many cancers but have not shown benefit in prostate cancer. Chronic inflammation contributes to the immunosuppressive prostate tumor microenvironment and is associa…
View article: Table S2 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S2 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Supplemental table 2
View article: Table S5 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S5 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Supplemental table 5
View article: Data from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Data from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Purpose:Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain affect protein function. We developed a FOXA1<…
View article: Figure 4 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 4 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Treatment-associated outcomes by FOXA1 alteration class. The survival analysis is conducted on patients who received (A) first-line ADT, including goserelin, leuprolide, triptorelin, degarelix, and relugolix. B, Second…
View article: Supplementary Figure 1-10 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Supplementary Figure 1-10 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Supplementary Figures 1-10
View article: Figure 5 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 5 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Molecular associations by FOXA1 alteration class. Percentages of (A) TMPRSS2–ERG fusions, (B) TP53 mutations, (C) MSI-high status, and (D) TMB-high status based on FOXA1 alteration cl…
View article: Figure 1 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 1 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
FOXA1 alterations in prostate cancer. A, Bar graphs showing percentages of amplifications and mutations found in the top 20 cancers with FOXA1 alterations from the Caris Life Sciences POA database. CUP, carcinoma of un…
View article: Figure 2 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 2 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
FOXA1 alterations and implications on protein structure. A, Distinctions between our classification scheme and two seminal studies are shown through an alluvial plot. B, MTR of each AA position of FOXA1. Horizontal lin…
View article: Figure 6 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 6 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
FOXA1 alteration classes by race. A, FOXA1 alteration classes are examined by race. B, The distribution of FOXA1 alteration classes by race. *q value <0.05, **q value <0.01, ***q value < 0.001, ****q valu…
View article: Figure 3 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 3 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
OS based on FOXA1 alteration class. OS is depicted based on forest plots as organized by each FOXA1 alteration class for (A) all prostate tumors, (B) prostate samples, and (C) metastatic samples. D,
View article: Supplementary Table 1-11 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Supplementary Table 1-11 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Supplementary Tables 1-11
View article: Table 1 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Table 1 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Patient demographics.
View article: Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain affect protein function. We developed a FOXA1 classific…
View article: Supplementary Table S4 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer
Supplementary Table S4 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer Open
Supplementary Table S4
View article: Supplementary Table S2 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer
Supplementary Table S2 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer Open
Supplementary Table S2
View article: Supplementary Table S3 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer
Supplementary Table S3 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer Open
Supplementary Table S3
View article: Supplementary Table S1 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer
Supplementary Table S1 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer Open
Supplementary Table S1
View article: Supplementary Table S2 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer
Supplementary Table S2 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer Open
Supplementary Table S2
View article: Supplementary Table S4 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer
Supplementary Table S4 from Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer Open
Supplementary Table S4